First half 2023 total revenues with double-digit growth of 15.1% at €24.6 million Both Pharma and Diagnostics segments deliver strong performance, reaffirming full year 2023 guidance for total revenue ...
Centogene, a commercial-stage company, and Fujirebio Europe announced to have entered a partnership to leverage Lumipulse G technology for large-scale COVID-19 antigen testing with further deployment ...
Aims to resolve patient diagnostic odyssey, often spanning years and multiple misdiagnoses before accurate diagnosis Combines cutting-edge technology and streamlined CE-IVD bioinformatics pipeline ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Providing patients with genetic testing designed to accelerate the diagnosis and personalized treatment of Parkinson’s disease (PD) The Rostock International Parkinson's Disease (ROPAD) Study aims to ...
Centogene NV and Twist Bioscience Corp. are linking up to develop custom assay kits for rare disease testing. The companies said the collaboration aims to make genetic tests more accessible to rare ...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, ...
In June 2020, CENTOGENE announced a partnership with Lufthansa and Fraport, the operator of Frankfurt airport, to open the first COVID-19 walk-in test center at Frankfurt Airport, providing on-site ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results